In a high-throughput screening with commercially available SPHK inhibitors (i.e., ABC294640, mp-A08, PF-543, and SLP7111228) and the S1P receptor (S1PR) antagonist (VPC 23019), NMDS was established as the most potent inhibitor against representative IDHmut gliomas [11]. This evidence concerns the gene SPHK1 and central nervous system cancer.